Influenza A Virus Vaccines and Inhibitors

2-32. (canceled)

A crystal of the complex between NS1(85-215) and the CPSF30 F2F3 fragment. and variants, wherein the crystal is of sufficient quality to obtain atomic coordinates by X-ray crystallography.

An antiviral drug comprising an F3 Zn-finger molecule of CPSF30, and variants thereof, adapted for use against influenza A infection in humans, poultry, and other livestock.

A process for engineering a live attenuated influenza A virus vaccine by mutation of specific residues in the CPSF30-binding site of the NS1A protein, a tetramer interface and combinations thereof, based on the 3D structure of the complex formed between NS1A (85-215) and F2F3.

An attenuated influenza A virus vaccine comprising eight viral RNA segments, wherein a viral RNA segment eight has a first mutation that causes a substitution of a first amino acid corresponding to an amino acid of SEQ. ID. NO. 1 at a position F103, L105, M106, K110, I117, I119, Q121, D125, L144, V180, G183, G184, W187;

• corresponding positions in other influenza A strains and combinations thereof, wherein the first mutation decreases the CPSF30 binding ability of the NS1A protein.

A pharmaceutical composition comprising a live attenuated influenza A virus vaccine by mutation of specific residues in the CPSF30-binding site, a tetramer interface and combinations thereof, of the NS1A protein, based on the 3D structure of the complex formed between NS1A (85-215) and F2F3 of CPSF30, and a pharmaceutically acceptable carrier or diluent.

A method of prophylaxis of a disease condition caused by the influenza A virus comprising administering to a subject in need thereof a therapeutically effective amount of a live attenuated influenza A virus vaccine by mutation of specific residues in the CPSF30-binding site, a tetramer interface, and combinations thereof, of the NS1A protein based on the 3D structure of the complex formed between NS1A (85-215) and F2F3.